Jerini AG

Discovery and development of novel peptide-based drugs; pepide array platforms

Jerini AG was founded in 1994 as a spin-off from the Medical Faculty of the Humboldt University in Berlin to commercialize the SPOT™ technology. Shares of the company were for the first time trade on the Frankfurt Stock Exchange on 1 Nov. 2005 (JI4).

JPT Peptide Technologies GmbH (JPT)is a wholly-owned subsidiary of Jerini

Jens Schneider-Mergener (CEO)
Adi Hoess (Chief Commercial Officer)
Jochen Knolle (Chief Scientific Officer, Head of Research & Development)
Berndt Modig (CFO)
Stacy Wiedenmann (Director Investor Relations &
Corporate Communications)

Dr. Holger Wenschuh (Manager of JPT Technologies GmbH)
Dr. Mike Schutkowski(Manager of JPT Technologies GmbH)

Dr. Karl-Gerhard Seifert
Dr. Hubert Birner
Dr. Björn Odlander
Dr. Stephan Goetz
Dr. Klaus Stöckemann
Dr. Peter Johann

Invalidenstrasse 130
10115 Berlin
Germany
Phone: +49-30-978 93-285
Fax: +49-30-978 93-599

JPT Peptide Technologies GmbH is however at:
Volmerstrasse 5 (UTZ)
12489 Berlin, Germany
Phone +49 (0)30-6392-7878
Fax: +49 (0)30-6392-7888

E-mail and URL take you directly to JPT

The company’s proprietary Peptides-to-Drugs (P2D) discovery platform is the basis for Jerini’s lead drug candidate. Icatibant is currently undergoing Phase III clinical trials in Europe, USA and other countries testing the suitability of the drug for the subcutaneous treatment of hereditary angioedema (HAE). The company has compounds in the pipeline for the treatment of age-related macular degeneration.

The subsidary JPT Peptide Technologies focusus on pepdide arrays. The PepSpot™ and PepStar™ (microarrays on glass slides) platforms enable the study of protein-protein interactions. The peptide arrays are used for profiling kinases, phosphatases and proteases. PepSpot™ enables the production of hundreds of identical peptide arrays.